PRNewsWire · ABT · October 23, 2026

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Get the app for more

Explore stock news, insights and company research.